Her scientific interests lie mostly in Inflammatory bowel disease, Immunology, Internal medicine, Crohn's disease and Ulcerative colitis. Her study on Inflammatory bowel disease is covered under Disease. Marla Dubinsky has included themes like Genetics and Genome-wide association study, Single-nucleotide polymorphism in her Immunology study.
Her Internal medicine research is multidisciplinary, relying on both Gastroenterology, Surgery and Pathology. Her Crohn's disease research includes themes of Adalimumab, Clinical trial, Infliximab, Hazard ratio and Severity of illness. Her biological study spans a wide range of topics, including Maintenance therapy, NOD2, Biomarker, Physical therapy and Pediatrics.
Marla Dubinsky spends much of her time researching Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Gastroenterology and Crohn's disease. Marla Dubinsky works mostly in the field of Internal medicine, limiting it down to topics relating to Surgery and, in certain cases, Ileal Pouch Anal Anastomosis, as a part of the same area of interest. She interconnects Pregnancy, Serology, Immunology and Intensive care medicine in the investigation of issues within Inflammatory bowel disease.
The various areas that she examines in her Immunology study include Microbiome and Genome-wide association study. Her Ulcerative colitis study combines topics from a wide range of disciplines, such as Pouch, Tofacitinib, Colitis and Family medicine. Her Crohn's disease study deals with the bigger picture of Disease.
Marla Dubinsky focuses on Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology. Her study in the fields of Colectomy, Vedolizumab, Cohort and Pouchitis under the domain of Internal medicine overlaps with other disciplines such as In patient. Her Inflammatory bowel disease study contributes to a more complete understanding of Disease.
Marla Dubinsky has researched Ulcerative colitis in several fields, including Tofacitinib, Defecation, Quality of life, Bowel urgency and Adult patients. Her study in Crohn's disease is interdisciplinary in nature, drawing from both Irritable bowel syndrome, Disease management, Therapeutic drug monitoring and Hazard ratio. Marla Dubinsky interconnects Infliximab, Ileal Pouch Anal Anastomosis, Gene signature, Calprotectin and Serology in the investigation of issues within Gastroenterology.
Marla Dubinsky mostly deals with Inflammatory bowel disease, Internal medicine, Crohn's disease, Ulcerative colitis and Disease. Her studies deal with areas such as Tumor necrosis factor alpha, Multiplex, Colitis, Incidence and Etiology as well as Inflammatory bowel disease. Her Internal medicine research incorporates themes from Gastroenterology and Gene expression.
The concepts of her Crohn's disease study are interwoven with issues in Odds ratio, Pregnancy, Intensive care medicine and Hazard ratio. In the subject of general Ulcerative colitis, her work in Colectomy is often linked to Colorectal surgery, thereby combining diverse domains of study. Disease and Immunology are frequently intertwined in her study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins;Stephan Ripke;Rinse K Weersma;Richard H Duerr.
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
Andre Franke;Dermot P B McGovern;Jeffrey C. Barrett;Kai Wang.
Nature Genetics (2010)
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
Carl A. Anderson;Gabrielle Boucher;Charlie W. Lees;Andre Franke.
Nature Genetics (2011)
Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.
Arie Levine;Anne Griffiths;James Markowitz;David C Wilson.
Inflammatory Bowel Diseases (2011)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch.
The American Journal of Gastroenterology (2015)
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
Marla C. Dubinsky;Stéphanie Lamothe;Hui Ying Yang;Stephan R. Targan.
Interactions Between Commensal Fungi and the C-Type Lectin Receptor Dectin-1 Influence Colitis
Iliyan D Iliev;Vincent A Funari;Vincent A Funari;Kent D Taylor;Quoclinh Nguyen.
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease.
Manuel A. Rivas;Manuel A. Rivas;Manuel A. Rivas;Mélissa Beaudoin;Agnes Gardet;Christine Stevens.
Nature Genetics (2011)
Genome-wide association identifies multiple ulcerative colitis susceptibility loci
Dermot P.B. McGovern;Agnès Gardet;Leif Törkvist;Philippe Goyette.
Nature Genetics (2010)
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
Isabelle Cleynen;Isabelle Cleynen;Gabrielle Boucher;Luke Jostins;Luke Jostins;Luke Jostins;L Philip Schumm.
The Lancet (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: